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Abstract Tumors are composed of many different cell types including cancer cells, fibroblasts,
and immune cells. Dissecting functional metabolic differences between cell types within a mixed
population can be challenging due to the rapid turnover of metabolites relative to the time needed
to isolate cells. To overcome this challenge, we traced isotope-labeled nutrients into
macromolecules that turn over more slowly than metabolites. This approach was used to assess
differences between cancer cell and fibroblast metabolism in murine pancreatic cancer organoid-
fibroblast co-cultures and tumors. Pancreatic cancer cells exhibited increased pyruvate
carboxylation relative to fibroblasts, and this flux depended on both pyruvate carboxylase and
malic enzyme 1 activity. Consequently, expression of both enzymes in cancer cells was necessary
for organoid and tumor growth, demonstrating that dissecting the metabolism of specific cell
populations within heterogeneous systems can identify dependencies that may not be evident from
studying isolated cells in culture or bulk tissue.
Introduction
Tumors are composed of a heterogeneous mix of cell types, including cancer cells and stromal cells
such as fibroblasts, macrophages, and other immune cells. How these different cell types interact to
enable tumor growth is poorly understood. Environmental context plays an important role in deter-
mining how cancer cells use nutrients to proliferate and survive, and non-cancer cells within a tissue
can alter nutrient availability (Lyssiotis and Kimmelman, 2017; Mayers and Vander Heiden, 2017;
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Muir et al., 2018; Pavlova and Thompson, 2016; Sullivan and Vander Heiden, 2019). There is evi-
dence that different cell populations within tumors can compete for limiting nutrients (Chang et al.,
2015; Ho et al., 2015; Zecchin et al., 2017), and metabolic cooperation between different cell
types can also influence tumor phenotypes (Linares et al., 2017; Sousa et al., 2016; Valencia et al.,
2014; Vander Heiden and DeBerardinis, 2017). Nevertheless, technical challenges associated with
studying the metabolism of individual cell types within a mixed population have limited a complete
understanding of the metabolic interactions between cells in tumors. More broadly, this challenge
has been a barrier to study how cells use nutrients differently within tissues to support both normal
and disease physiology.
Cancer cell metabolism in culture can differ from the metabolism of tumors in vivo (Biancur et al.,
2017; Cantor et al., 2017; Davidson et al., 2016; Mayers and Vander Heiden, 2015; Muir et al.,
2017; Sellers et al., 2019; Vande Voorde et al., 2019). This can at least partially be ascribed to
changes in cancer cell metabolism that are driven by different nutrients present in the extracellular
environment; however, another major difference between cell culture and tumors is the presence of
additional cell types within tumors that are absent from most culture systems. The presence of many
different cell types complicates the ability to characterize cancer cell metabolism in tumors, particu-
larly in cases where a minority of the tumor is composed of cancer cells. For instance, cancer cells
are a minority cell type in pancreatic ductal adenocarcinoma (PDAC) tumors (Feig et al., 2012), and
an understanding of cell metabolism in these tumors requires de-convolution of cancer-specific and
stroma-specific phenotypes. Furthermore, there is evidence that the metabolism of cancer cells and
different stromal cells isolated from these tumors can be different from each other when studied in
culture (Francescone et al., 2018; Halbrook et al., 2019; Sousa et al., 2016), and it is unknown
eLife digest Tumors contain a mixture of many different types of cells, including cancer cells
and non-cancer cells. The interactions between these two groups of cells affect how the cancer cells
use nutrients, which, in turn, affects how fast these cells grow and divide. Furthermore, different cell
types may use nutrients in diverse ways to make other molecules – known as metabolites – that the
cell needs to survive.
Fibroblasts are a subset of non-cancer cells that are typically found in tumors and can help them
form. Separating fibroblasts from cancer cells in a tumor takes a lot longer than the chemical
reactions in each cell of the tumor that produce and use up nutrients, also known as the cell’s
metabolism. Therefore, measuring the levels of glucose (the sugar that is the main energy source for
cells) and other metabolites in each tumor cell after separating them does not necessarily provide
accurate information about the tumor cell’s metabolism. This makes it difficult to study how cancer
cells and fibroblasts use nutrients differently.
Lau et al. have developed a strategy to study the metabolism of cancer cells and fibroblasts in
tumors. Mice with tumors in their pancreas were provided glucose that had been labelled using
biochemical techniques. As expected, when the cell processed the glucose, the label was
transferred into metabolites that got used up very quickly. But the label also became incorporated
into larger, more stable molecules, such as proteins. Unlike the small metabolites, these larger
molecules do not change in the time it takes to separate the cancer cells from the fibroblasts.
Lau et al. sorted cells from whole pancreatic tumors and analyzed large, stable molecules that
can incorporate the label from glucose in cancer cells and fibroblasts. The experiments showed that,
in cancer cells, these molecules were more likely to have labeling patterns that are characteristic of
two specific enzymes called pyruvate carboxylase and malic enzyme 1. This suggests that these
enzymes are more active in cancer cells. Lau et al. also found that pancreatic cancer cells needed
these two enzymes to metabolize glucose and to grow into large tumors.
Pancreatic cancer is one of the most lethal cancers and current therapies offer limited benefit to
many patients. Therefore, it is important to develop new drugs to treat this disease. Understanding
how cancer cells and non-cancer cells in pancreatic tumors use nutrients differently is important for
developing drugs that only target cancer cells.
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whether the metabolic programs used by different cell populations in culture are also used within
PDAC tumors in vivo where environmental conditions are different.
Studies of bulk tumor metabolism fail to capture information about metabolic heterogeneity with
regard to different cell types (Xiao et al., 2019), and existing approaches are limited in their ability
to study functional metabolic phenotypes in different cell populations in intact tissue. A major limita-
tion arises from the fact that metabolic reactions take place on time scales that are faster than the
turnover of many metabolic intermediates, complicating metabolite analysis after tumor digestion
and cell sorting (Shamir et al., 2016). Furthermore, cell sorting exposes cells to conditions that are
different from those experienced by cells in tissues and can change metabolism in many ways. For
example, sorting can induce mechanical and oxidative stress and reduce the levels of certain metab-
olites (Binek et al., 2019; Llufrio et al., 2018; Roci et al., 2016), and even adding small amounts of
bovine serum to the sorting buffer was not sufficient to prevent changes in some metabolite levels
during cell sorting (Llufrio et al., 2018). Indeed, isotopic metabolite labeling patterns can be more
robust than metabolite levels when assessing metabolites from flow cytometry sorted cells, although
labeling can also be affected by cell sorting (Roci et al., 2016). Nevertheless, interpretation of
metabolite labeling patterns is influenced by whether cells are at metabolic steady state
(Buescher et al., 2015), which when coupled with the rapid timescales of metabolism relative to the
time needed to isolate cells suggests that new approaches are needed to better understand metab-
olism of individual cell types within mixed cell populations such as tumors.
To overcome the challenges associated with studying cell metabolism within intact tumors and
organoid co-cultures, we adapted an approach based on end-product biomass labeling
(Green et al., 2016; Hosios et al., 2016; Le et al., 2017; Lewis et al., 2014; Mayers et al., 2016;
Shankaran et al., 2016). This technique has been applied in studies of microbial metabolism and
metabolic engineering to better understand mixed populations of bacteria (Gebreselassie and
Antoniewicz, 2015; Ghosh et al., 2014; Ru¨hl et al., 2011; Zamboni et al., 2005). Unlike short-lived
metabolic intermediates, turnover of end-product macromolecules such as protein is slow relative to
the time period needed to isolate tumor cell populations. By assessing the isotope-labeling pattern
of end-product biomass generated when cells are exposed to labeled nutrients in a mixed cell popu-
lation, metabolic differences in nutrient use by different cells can be inferred. We used this approach
to uncover a difference in glucose metabolism between cancer cells and fibroblasts in PDAC. Specifi-
cally, we find that, relative to fibroblasts, cancer cells within PDAC tumors have increased use of glu-
cose for tricarboxylic acid (TCA) cycle anaplerosis through increased flux through pyruvate
carboxylase (PC). This phenotype is not evident when cancer cells and fibroblasts are studied as sep-
arate populations in mono-culture, even though PC is necessary for tumor growth in vivo. Further-
more, deletion of PC was insufficient to account for all pyruvate carboxylation activity within cancer
cells in a mixed population, revealing that malic enzyme 1 (ME1) also contributes to pyruvate carbox-
ylation in cancer cells when fibroblasts are present and is required for PDAC tumor growth. These
data argue that tracing labeled nutrients into stable biomass can be used to reveal metabolic differ-
ences between subpopulations of cells in a mixed cell system and to identify phenotypes that
depend on the co-existence of multiple cell types.
Results
Glucose metabolism in pancreatic tumors
PDAC involves tumors where cancer cells can be a minority cell population (Feig et al., 2012). To
better understand glucose metabolism of PDAC tumor tissue in vivo, we infused U-13C-glucose into
conscious, unrestrained mice (Davidson et al., 2016; Hui et al., 2017; Marin-Valencia et al., 2012)
bearing PDAC tumors from autochthonous models that are driven by activating mutations in Kras
and disruption of Trp53 function (Bardeesy et al., 2006; Hingorani et al., 2005). Similar to what has
been observed with other mouse cancer models and in humans (Davidson et al., 2016; Fan et al.,
2009; Hensley et al., 2016; Sellers et al., 2015), extensive labeling of multiple metabolic intermedi-
ates is observed from U-13C-glucose in pancreatic tumors and normal pancreas (Figure 1, Figure 1—
figure supplements 1–3, Figure 1—source data 1, Figure 1—figure supplement 1—source data
1, Figure 1—figure supplement 2—source data 1, Figure 1—figure supplement 3—source data
1).
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Figure 1. Glucose metabolism in PDAC tumors. (A) Plasma glucose levels over time in autochthonous LSL-KrasG12D/+; Trp53fl/fl; Pdx1-Cre (KP-/-C) or
autochthonous LSL-KrasG12D/+; Trp53R172H/+; Pdx1-Cre (KPC) pancreatic tumor-bearing mice infused with U-13C-glucose at a rate of 0.4 mg/min. n = 3
for each group. Mean +/- SEM is shown. (B) Enrichment of fully labeled glucose (M+6) in plasma from the indicated mice following a 6 hr U-13C-glucose
infusion at a rate of 0.4 mg/min. Non-tumor bearing C57Bl6/J (WT) mice were used to assess metabolite labeling in normal pancreas. WT, n = 4; KP-/-C,
Figure 1 continued on next page
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To assess U-13C-glucose labeling of metabolites in autochthonous pancreatic tumors arising in
the LSL-KrasG12D; Trp53fl/fl; Pdx1-Cre (KP-/-C) (Bardeesy et al., 2006) and the LSL-KrasG12D;
Trp53R172H/+; Pdx1-Cre (KPC) (Hingorani et al., 2005) mouse models, we first confirmed that plasma
glucose levels were not changed over the course of the experiment (Figure 1A). At this rate of glu-
cose infusion, enrichment of 13C-glucose in plasma was around 40% in non-tumor-bearing mice, and
in both KP-/-C and KPC animals (Figure 1B). Glucose enrichment was not measured in tumors, as
glucose is thought to be rapidly metabolized after entry into cells (Nguyen et al., 2011;
Parikh et al., 2015; Yeh et al., 2018). Under these conditions, labeling of pyruvate and lactate, as
well as the glucose-derived amino acids alanine and serine, from U-13C-glucose was observed in nor-
mal pancreas tissue and in tumors arising in both models (Figure 1C–F, Figure 1—source data 1).
Labeling of TCA cycle metabolites was also observed in normal pancreas tissue and in PDAC
tumors from both models (Figure 1G–L, Figure 1—source data 1). Carbon from glucose-derived
pyruvate can contribute to the TCA cycle via reactions catalyzed by pyruvate dehydrogenase (PDH)
or pyruvate carboxylase (PC), and the relative use of these routes of TCA cycle labeling has been
inferred from the labeling pattern of TCA cycle intermediates from 13C-labeled glucose
(Davidson et al., 2016; Fan et al., 2009; Hensley et al., 2016; Sellers et al., 2015). PDH decarbox-
ylates three-carbon pyruvate to two-carbon acetyl-CoA, and therefore if 13C-labeled pyruvate is
metabolized via PDH, a two carbon (M+2) labeling pattern is observed in TCA cycle metabolites as
well as in the amino acid aspartate (Figure 1G). In contrast, PC carboxylates three-carbon pyruvate
to four-carbon oxaloacetate, and therefore if unlabeled CO2 is added to
13C-labeled pyruvate via
this enzyme, a three carbon (M+3) labeling pattern is observed (Figure 1G). We observed an
increase in both M+2 and M+3 labeling of TCA cycle metabolites and the TCA cycle-derived amino
acids aspartate and glutamate in KP-/-C tumor tissue compared to normal pancreas (Figure 1H–N).
Importantly, despite some aspartate labeling in the plasma of infused mice (Figure 1—figure sup-
plement 1J, Figure 1—figure supplement 1—source data 1), prior studies of this model have
shown that cancer cells cannot take up extracellular aspartate (Sullivan et al., 2018), arguing that
labeled aspartate in plasma contributes minimally to aspartate labeling in cancer cells in PDAC
tumors. Proline was not extensively labeled from glucose in pancreas or PDAC tumor tissue from
either model, suggesting that glucose carbon contributes minimally to the synthesis of this amino
acid (Figure 1O, Figure 1—source data 1). Of note, in KPC mouse PDAC tumors, we observed
higher M+2 labeling of only some TCA cycle metabolites compared to normal pancreas, and did not
observe an increase in M+3 metabolite labeling compared to pancreas (Figure 1H–O), illustrating
Figure 1 continued
n = 3, KPC, n = 3. Differences in plasma glucose enrichment were not significant between WT and KP-/-C mice (p=0.8723), WT and KPC mice
(p=0.1907), or KP-/-C and KPC tumor-bearing mice (p=0.1512) based on unpaired, two-tailed student’s t tests. Mean +/- SEM is shown. (C–F) The
fractional labeling of pyruvate (C), lactate (D), alanine (E), and serine (F) in pancreas (black), autochthonous KP-/-C pancreatic tumors (dark blue), or
autochthonous KPC pancreatic tumors (light blue) following a 6 hr U-13C-glucose infusion at a rate of 0.4 mg/min. The M+3 isotopomers are shown for
each metabolite: n = 3 for each group. Mean +/- SEM is shown. (G) Schematic illustrating how U-13C-glucose can label TCA cycle intermediates. An
M+2 labeling pattern of TCA cycle intermediates can be derived from flux through pyruvate dehydrogenase (PDH) (left) while an M+3 labeling pattern
can reflect flux through pyruvate carboxylase (PC) (right). (H–O) The fractional labeling of citrate (M+3; WT vs. KP-/-C p=0.0012, KP-/-C vs. KPC p=0.0084)
(H), a-ketoglutarate (aKG) (I), succinate (J), fumarate (K), malate (M+3 KP-/-C vs. KPC p=0.0156) (L), aspartate (M+3 WT vs. KPC p=0.0194) (M),
glutamate (M+2 WT vs. KP-/-C p=0.0089) (N), and proline (O) in pancreas (black), autochthonous KP-/-C pancreatic tumors (dark blue), or autochthonous
KPC pancreatic tumors (light blue) following a 6 hr U-13C-glucose infusion at a rate of 0.4 mg/min. Significance based on unpaired, Students t-test. The
M+2 and M+3 isotopomers are shown for each metabolite, n = 3 for each group. Mean +/- SEM is shown.
The online version of this article includes the following source data and figure supplement(s) for figure 1:
Source data 1. Isotope labeling of tumors in U-13C- glucose-infused mice with autochthonous PDAC tumors presented in Figure 1.
Figure supplement 1. Metabolite abundance and plasma labeling in U-13C- glucose-infused autochthonous PDAC tumors.
Figure supplement 1—source data 1. Tumor metabolite abundance and plasma isotope labeling in U-13C- glucose-infused mice with autochthonous
PDAC tumors presented in Figure 1—figure supplement 1.
Figure supplement 2. Glucose metabolism in autochthonous PDAC tumors infused with U-13C- glucose at 30 mg/kg/min.
Figure supplement 2—source data 1. Isotope labeling of tumors in U-13C- glucose-infused mice with autochthonous PDAC tumors presented in Fig-
ure 1—figure supplement 2.
Figure supplement 3. Glucose metabolism in autochthonous and orthotopic PDAC tumors infused with U-13C-glucose at 30 mg/kg/min.
Figure supplement 3—source data 1. Plasma isotope labeling in 13C- glucose-infused mice with autochthonous PDAC tumors and metabolite isotope
labeling in orthotopic PDAC tumors presented in Figure 1—figure supplement 3.
Lau et al. eLife 2020;9:e56782. DOI: https://doi.org/10.7554/eLife.56782 5 of 35
Research article Cancer Biology
that glucose labels metabolites differently in bulk tumors arising in each model. These data suggest
that glucose contributes to labeling of TCA cycle carbon via reactions that involve PDH and PC in
PDAC tumors, although the extent of labeling depends on the PDAC model used.
To further study glucose metabolism in PDAC tumor tissue, we infused control and tumor-bearing
KP-/-C mice with U-13C-glucose at a higher rate in an attempt to increase plasma enrichment of
labeled glucose (Davidson et al., 2016; Figure 1—figure supplement 2, Figure 1—figure supple-
ment 3A–K, Figure 1—figure supplement 2—source data 1, Figure 1—figure supplement 3—
source data 1). Plasma glucose levels were increased as a result of this higher infusion rate (Fig-
ure 1—figure supplement 2B), and resulted in extensive labeling of glycolytic metabolites and glu-
cose-derived amino acids (Figure 1—figure supplement 2C–F, Figure 1—figure supplement 2—
source data 1), as well as an increase in M+2 and M+3 labeling of TCA cycle intermediates and
related amino acids in pancreatic tumor tissue relative to normal pancreas (Figure 1—figure supple-
ment 2G–N, Figure 1—figure supplement 2—source data 1). These data further support that glu-
cose carbon can contribute label to TCA cycle intermediates via pathways that involve PDH and PC
in PDAC tumors, but the relative contribution varies based on plasma glucose levels and the PDAC
model examined.
Despite both being driven by mutant Kras and loss of normal Trp53 function, differences in the
autochthonous KP-/-C and KPC PDAC models are known and have been attributed to differences in
tumor latency and p53 status, as well as differences in how stromal cell populations interact with can-
cer cells to support tumor growth (Rosenfeldt et al., 2013; Vennin et al., 2019). Thus, a difference
in relative abundance of cancer and non-cancer cells, or in interactions between non-cancer cells and
cancer cells, are possible explanations for why differences in glucose labeling are observed across
these models. To explore whether the relative abundance of cancer cells in the tumor might affect
labeling, we infused mice with pancreatic tumors derived from orthotopic injection of a syngeneic
KrasG12D; Trp53-/- pancreatic cancer cell line derived from tumors arising in the KP-/-C model
(Danai et al., 2018), since cell line transplantation models are thought to result in tumors with a less
dense, desmoplastic stroma compared to autochthonous models (Baker et al., 2016; Olive et al.,
2009). When compared to adjacent normal pancreas, we observed an increase in M+2 and M+3
labeling of TCA metabolites and aspartate in this orthotopic tumor model (Figure 1—figure supple-
ment 3L–O, Figure 1—figure supplement 3—source data 1). Regardless, tumors arising from
orthotopic transplantation of murine PDAC cells still contain stroma (Danai et al., 2018). Thus,
tumors in all models considered consist of multiple cell types, and cancer cells are known to be a
minority cell population in both autochthonous PDAC tumor models. In all cases, metabolite labeling
will reflect a weighted average of labeling in all cell types present in the tissue sample and this het-
erogeneity in cell types in all tissues is a limitation to the use of labeled nutrient infusions to under-
stand the metabolism of cancer cells, or any individual cell population, in tumors or other tissues.
Assessment of pyruvate carboxylation activity in different PDAC tumor
cell populations using existing methods
Dissecting the metabolism of individual cell types within a mixed cell population is a barrier to identi-
fying cancer cell-specific liabilities via functional metabolic measurements in tumors such as PDAC.
Therefore, we sought to better understand the contribution of cancer cells to the labeling of TCA
cycle intermediates from 13C-glucose in PDAC tumors. We focused on M+3 labeling of TCA cycle
intermediates from glucose, reflective of pyruvate carboxylation activity, because this is a metabolic
phenotype observed in tumors that is less prominent in cancer cells in culture (Davidson et al.,
2016). One existing approach to determine which cell type within the tumor contributes to this activ-
ity is to evaluate expression of an enzyme known to catalyze this reaction. Indeed, immunohis-
tochemistry (IHC) analysis of tumors arising in KP-/-C mice revealed higher PC expression in cancer
cells (Figure 2A). Analysis of a human pancreatic tumor tissue by IHC shows that human tumors
exhibit a range of PC expression levels (Figure 2—figure supplement 1A–D), although higher PC
expression is observed in cancer cells compared to stroma (Figure 2B), similar to findings in human
lung tumors (Sellers et al., 2015). However, while IHC can be useful to determine relative expression
in tumor sections, it does not prove lack of expression by non-cancer cells. Indeed, qPCR analysis of
mRNA isolated from sorted cell populations derived from KP-/-C tumors trended toward higher PC
expression in cancer cells relative to fibroblasts, although PC mRNA was detected in fibroblasts
(Figure 2C). Furthermore, metabolic fluxes can be more dependent on metabolite concentrations
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Figure 2. Assessment of pyruvate carboxylase activity in PDAC cancer cells and fibroblasts. (A) Sections from tumors arising in LSL-KrasG12D/+; Trp53fl/fl;
Pdx1-Cre (KP-/-C) mice were stained with an antibody against pyruvate carboxylase. Scale bar represents 100 mm. (B) Representative image from a
human pancreatic tumor tissue microarray that was stained with an antibody against pyruvate carboxylase. Scale bar represents 100 mm. (C) Pyruvate
carboxylase expression was assessed by qPCR in whole PDAC tumors and different cell populations in sorted from PDAC tumors arising KP-/-C mice.
The difference in expression between sorted cancer cells and the whole tumor (p=0.5485) or between sorted cancer cells and fibroblasts from tumors
was not significant (p=0.0722) based on unpaired, two-tailed student’s t-tests. Mean +/- SEM is shown. 36B4 was used as a housekeeping gene control.
(D–F) The fractional labeling of aspartate (D) or malate (E) in cultured murine PDAC cells derived from tumors in KP-/-C mice (black) and in cultured
Figure 2 continued on next page
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than enzyme expression levels (Hackett et al., 2016). Therefore, increased enzyme expression may
not reflect increased activity in tissues, and argues that while suggestive, expression analysis is not
definitive for identifying which cell population is responsible for M+3 TCA cycle labeling from glu-
cose in pancreatic tumors.
Another approach that has been used to determine which cell type(s) within the tumor contribute
to a metabolic activity is isolating distinct cell populations and studying them in culture (Dalin et al.,
2019; Francescone et al., 2018; Linares et al., 2017; Sousa et al., 2016; Valencia et al., 2014;
Yang et al., 2016). Pancreatic stellate cells (PSCs) are a type of resident fibroblast in the pancreas
which can become activated during tumorigenesis and impact the tumor microenvironment
(Bynigeri et al., 2017; Dune´r et al., 2011). When PDAC cells or PSCs alone are cultured in the pres-
ence of 13C-glucose in vitro, PSCs exhibit similar or higher M+3 TCA cycle metabolite labeling than
cancer cells (Figure 2D–E), even though the fibroblast cell population exhibited lower PC expression
in tumors (Figure 2A–B). These data further highlight the challenges associated with ascribing func-
tional metabolic phenotypes using enzyme expression alone. Nevertheless, isolated cell populations
in culture also may not retain the same functional metabolic phenotypes found within tumor tissue
where many different cells compete for available nutrients.
To develop new approaches to study the phenotype of individual cell types in a mixed cell popu-
lation, we first sought to generate a more tractable system that only involves interactions between
two different cell types. One approach is to use organoid cultures involving PDAC cancer cells and
fibroblasts (O¨hlund et al., 2017) where nutrient conditions are modified such that cancer cells rely
on the presence of the fibroblasts to proliferate. To do this, we generated pancreatic cancer orga-
noid cultures from KP-/-C and KPC tumors (Figure 2—figure supplement 1E; Boj et al., 2015), and
found that when exposed to a more minimal medium than is commonly used (Boj et al., 2015), pan-
creatic cancer organoid growth becomes dependent on including PSCs in the culture system
(Figure 2F–G, Figure 2—figure supplement 1F–G). Relevant to the M+3 labeling of TCA cycle-
associated metabolites from glucose observed in pancreatic tumors, when sorted from this co-cul-
ture organoid system, both cancer cells and PSCs expressed higher levels of PC mRNA compared to
PSCs and pancreatic cancer cells in standard monoculture (Figure 2H). In addition, when U-13C-glu-
cose is provided to whole organoid co-cultures comprised of both cancer cells and PSCs, and TCA
cycle intermediate labeling is assessed after rapid quenching and extraction of metabolites, M+3
labeling of aspartate and malate was observed (Figure 2I–J, Figure 2—figure supplement 1H–K,
Figure 2—source data 1). These data argue that this organoid co-culture system may provide a
model to explore the relative contribution of each cell population to the pyruvate carboxylation phe-
notype observed when both cell types are present.
Effect of cell sorting on metabolite levels and metabolite labeling from
extracellular nutrients
To dissect PDAC cancer cell versus other cell type contributions to specific metabolic activities, we
reasoned it would be necessary to isolate each cell type for analysis after exposure to labeled
Figure 2 continued
isolated pancreatic stellate cells (PSCs) (grey) was measured after exposure to U-13C-glucose for 24 hr. The M+2 and M+3 isotopomers are shown for
each metabolite. Mean +/- SD is shown. (F) Fluorescent images of KP-/-C PDAC cancer cell organoids expressing tdTomato cultured in
DMEM without pyruvate with 10% dialyzed FBS (top) or in the same media conditions with murine PSCs included in the culture (bottom). (G)
Quantification of tdTomato fluorescence from images in (G). Organoid cultures with PSCs included had significantly higher tdTomato fluorescence than
organoids cultured without PSCs (p=0.0014) based on an unpaired, two-tailed student’s t-test. Mean +/- SD is shown. (H) Expression of pyruvate
carboxylase as assessed by qPCR in PDAC cancer cells or PSC cells sorted from organoid co-cultures (3D) or in standard 2D culture as indicated. The
difference between cancer cells in 3D compared to PSCs in 3D (p=0.1071) was not significant, but the differences between cancer cells in 3D and
cancer cells in 2D (p=0.0140), cancer cells in 3D compared to PSCs in 2D (p=0.0209), PSCs in 3D compared to cancer cells in 2D (p<0.0001), and PSCs
in 3D compared to PSCs in 2D (p=0.0014) were significant based on unpaired, two-tailed student’s t-tests. Mean +/- SD is shown. (I–J) The fractional
labeling of aspartate (I) or malate (J) in murine PDAC organoid-PSC co-cultures was measured after 24 hr of exposure to U-13C-glucose. The M+2 and
M+3 isotopomers are shown for each metabolite. Mean +/- SD is shown.
The online version of this article includes the following source data and figure supplement(s) for figure 2:
Source data 1. Metabolite isotope labeling by U-13C- glucose in unsorted organoid-PSC co-cultures.
Figure supplement 1. Assessment of pyruvate carboxylase activity in PDAC cancer cells and fibroblasts.
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nutrients. To experimentally evaluate the effect of sorting cells from the organoid co-culture system
on metabolite levels and labeling from glucose, we cultured AL1376 murine PDAC cells in U-13C-glu-
cose and incubated the cells in buffer on ice for various lengths of time to simulate conditions the
cells would experience during separation by flow cytometry (up to 240 min) or other antibody based
methods, which require a minimum of 10–12 min (Abu-Remaileh et al., 2017; Chen et al., 2016).
Metabolite levels and labeling were then measured over time using mass spectrometry, allowing
comparison to that observed when metabolism is rapidly quenched (the zero time point). Consistent
with the known rapid turnover of metabolites (Shamir et al., 2016), the levels (Figure 3A–D, Fig-
ure 3—figure supplement 1A–C, Figure 3—source data 1) and/or labeling from U-13C-glucose
(Figure 3E–H, Figure 3—figure supplement 1D–F, Figure 3—source data 1), of many metabolites
changed over the time required to separate cells using antibodies and/or flow cytometry. These
changes indicate that metabolism is not at metabolic steady-state where levels and labeling of
metabolites are stable over time and could complicate interpretation of some differential isotope
labeling patterns (Buescher et al., 2015). In fact, changes in metabolite levels and labeling may be
even greater when using flow cytometry to sort cells in practice because temperature as well as fac-
tors such as mechanical stress are less easily controlled (Binek et al., 2019). While this does not
absolutely preclude an ability to gain information from metabolite measurements in sorted cells,
assessment of M+3 labeling of TCA cycle intermediates in sorted cell populations from organoids or
tumors may not fully portray the contribution of each cell type to the pyruvate carboxylation pheno-
type observed when material containing multiple cell types is analyzed.
The turnover of protein and nucleic acid is slow relative to metabolites (Shamir et al., 2016),
which allows gene expression and proteomic analysis in separated cell types to better reflect the
state of cells within a mixed population. Because metabolites contribute to protein, lipid, and nucleic
acid biomass, and isotope-labeled nutrients can be traced into this biomass (Gebreselassie and
Antoniewicz, 2015; Ghosh et al., 2014; Green et al., 2016; Hosios et al., 2016; Le et al., 2017;
Lewis et al., 2014; Mayers et al., 2016; Ru¨hl et al., 2011; Shankaran et al., 2016; Zamboni et al.,
2005), we reasoned that 13C-labeling patterns in biomass might be used to infer the contribution of
glucose to different metabolic pathways within a mixed cell population relevant to pancreatic cancer.
We confirmed that glucose labeling of protein was stable over the time period needed to sort cells
by flow cytometry (Figure 3I–J, Figure 3—source data 1). We also confirmed that amino acids from
protein hydrolysates were detectable in sorted cells from murine PDAC tumors, and were within the
linear range of detection by GC-MS even when low cell numbers of less abundant cell populations
were recovered from tumors (Figure 3—figure supplement 1G–L). Therefore, examining 13C label
in amino acids from hydrolyzed protein may be informative of the labeling of free amino acids in
tumor cell subpopulations that existed prior to sorting the cells.
Evidence for higher pyruvate carboxylation activity in cancer cells
relative to fibroblasts in PDAC models
To facilitate sorting of PSCs and PDAC cancer cells from organoid co-cultures and tumors, a LSL-
tdTomato reporter allele was bred to the KP-/-C and KPC PDAC models as a source of tdTomato+
cancer cells for both organoid and tumor models. PSCs were isolated from pancreata from mice
bearing a b-actin-GFP allele to enable sorting of GFP+ PSCs for labeling of the PSC population in
the organoid co-culture model (Figure 4A). To determine the relative contribution of 13C-glucose to
M+3-labeled aspartate in cancer cells and PSCs in the organoid-fibroblast co-culture model, we
exposed organoid co-cultures containing tdTomato+ cancer cells and GFP+ PSCs to U-13C-glucose
for 1–4 days prior to sorting cancer cells and PSCs, and then hydrolyzed protein for amino acid anal-
ysis from each cell population. Over time, similar M+2 protein aspartate labeling was observed
between the two cell types, while higher M+3 aspartate labeling was observed in cancer cells as
compared to PSCs, suggesting that while the two cell types have similar labeling via reactions involv-
ing PDH, the cancer cells appear to have higher pyruvate carboxylation activity (Figure 4B–C, Fig-
ure 4—source data 1). This higher M+3 level was also reflected in the other TCA cycle-derived
amino acids glutamate and proline (Figure 4D–G, Figure 4—source data 1), whereas labeling of
the glucose-derived amino acids alanine and serine was not higher in cancer cells (Figure 4—figure
supplement 1A–B, Figure 4—source data 1). We also exposed organoid co-cultures to U-13C-gluta-
mine over 4 days and traced the fate of labeled carbon into protein in each cell population. Of note,
we observed slightly higher labeling of aspartate from glutamine in protein in PSCs (Figure 4—
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Figure 3. Turnover of polar metabolites but not protein is fast relative to the time needed to sort cells. (A–D) Metabolite levels (total ion counts, TIC) of
(A) aspartate, (B) alanine, (C) malate, and (D) citrate were measured by GC-MS in AL1376 PDAC cells extracted 0–240 min after incubation in PBS on ice
to mimic optimal sorting conditions. Mean +/- SD is shown. (E–H) Fractional labeling of (E) aspartate, (F) alanine, (G) malate, and (H) citrate were
measured by GC-MS from cells extracted 0–240 min after incubation in PBS on ice. The M+3 isotopomer is shown. Mean +/- SD is shown. (I–J)
Fractional labeling of (I) aspartate and (J) alanine from protein hydrolysates were measured by GC-MS in cells extracted 0–240 min after incubation in
PBS on ice. The M+3 isotopomer is shown. Mean +/- SD is shown. Time points analyzed were 0 min (no PBS incubation), 5 min, 30 min, 120 min, or 240
min of incubation in PBS.
Figure 3 continued on next page
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figure supplement 1C, Figure 4—figure supplement 1—source data 1), matching the lower frac-
tional labeling we observed from glucose. We did not observe other appreciable differences in frac-
tional labeling of glutamate or proline from glutamine in protein between cancer cells and PSCs
(Figure 4—figure supplement 1D–E, Figure 4—figure supplement 1—source data 1). Taken
together, these data suggest a differential fate for glucose in these cell types, with increased M+3
labeling of aspartate from glucose carbon in cancer cells relative to PSCs.
Because the labeling of amino acids in protein is unlikely to reach steady-state even after multiple
days of labeling, one explanation for the difference in aspartate labeling from labeled glucose in the
cancer cells relative to the PSCs is a higher rate of protein synthesis in the cancer cells, although this
is unlikely to differentially affect only M+3 labeled species. Nevertheless, to examine this possibility,
we measured protein synthesis rates in each cell type using a fluorescent protein synthesis reporter
in which BFP is fused to an unstable E. coli dihydrofolate reductase (DHFR) domain. Upon addition
of the DHFR active site ligand trimethoprim (TMP), the reporter is stabilized and the rate of fluores-
cence accumulation reflects the synthesis rate of the fluorescent protein (Han et al., 2014). Consis-
tent with previous reports, this reporter produced similar results compared to an assessment of
protein synthesis through incorporation rates of the aminoacyl tRNA analog puromycin
(Darnell et al., 2018) when BFP accumulation after TMP addition was assayed over time in PDAC
cancer cell and PSC mono-cultures and compared to cells with no TMP added as a negative control
(Figure 4—figure supplement 1F–G). The BFP reporter is suitable for use in sorted cells from a
mixed cell system, and thus was used to assess protein synthesis rates in cancer cells and PSCs in
organoid co-cultures. Interestingly, even though cancer cells and PSCs exhibited a similar protein
synthesis rate in monoculture (Figure 4—figure supplement 1F–G), accumulation of BFP fluores-
cence was slower in cancer cells compared to PSCs in 3D co-cultures (Figure 4H). This argues that
protein synthesis rates are higher in PSCs in organoid co-cultures, and that the higher M+3 aspartate
labeling observed in cancer cells cannot be explained by a higher rate of protein synthesis in the
cancer cells in this co-culture system.
M+3 labeling from U-13C-glucose is often used as a surrogate for pyruvate carboxylation activity,
but can also occur from multiple rounds of TCA cycling (Alves et al., 2015). To more directly assess
pyruvate carboxylation activity in additional experiments with multiple replicates, we traced 1-13C-
pyruvate or 3,4-13C-glucose fate in organoid-PSC co-cultures. 1-13C-pyruvate or 3,4-13C-glucose can
only label aspartate via pyruvate carboxylation, because the 13C-label is lost as carbon dioxide if
pyruvate is metabolized to acetyl-coA via PDH prior to entering the TCA cycle (Figure 4I). Com-
pared to U-13C-glucose labeling, a greater difference and significantly higher M+1 aspartate labeling
in protein was observed using 1-13C-pyruvate or 3,4-13C-glucose in sorted cancer cells compared to
PSCs from organoid-PSC co-cultures, further supporting that pyruvate carboxylation activity is higher
in these cells (Figure 4J–K, Figure 4—figure supplement 1H). Taken together, these data argue
that cancer cells within PDAC organoid-PSC co-cultures have higher pyruvate carboxylation activity
than PSCs.
To investigate whether PDAC cancer cells also exhibit higher pyruvate carboxylation activity in
tumors in vivo, we first verified that the tdTomato fluorescence in tumors arising in KP-/-C mice bear-
ing a LSL-tdTomato allele did not co-localize with staining for the fibroblast-specific marker alpha-
smooth muscle actin (a-SMA) (Figure 5A), but did co-localize with Cytokeratin 19 (CK19), a marker
of pancreatic cancer cells (Figure 5B). This verifies that tdTomato labeling can be used to isolate
cancer cells from a-SMA-positive fibroblasts, and a combination of tdTomato fluorescence and an
antibody for the pan-hematopoietic marker CD45 allowed efficient sorting of cancer cells, fibro-
blasts, and hematopoietic cells as verified by expression of relevant mRNAs using qPCR (Figure 5C–
F, Figure 5—figure supplement 1A–B). To label protein in PDAC tumors in vivo, autochthonous
tumor-bearing mice were infused with U-13C-glucose for 24 hr (Figure 5—figure supplement 1C–
D), with aspartate labeling observed in protein hydrolysates from bulk tumors in this time frame
Figure 3 continued
The online version of this article includes the following source data and figure supplement(s) for figure 3:
Source data 1. Metabolite abundance, metabolite isotope labeling, and protein hydrolysate isotope labeling by U-13C- glucose in AL1376 PDAC cells.
Figure supplement 1. Turnover of polar metabolites but not protein is fast relative to the time needed to sort cells.
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Figure 4. PDAC cancer cells have higher pyruvate carboxylation activity than fibroblasts in organoid co-cultures. (A) A representative flow cytometry
plot showing GFP and tdTomato expression in PSCs and cancer cells respectively from digested organoid-PSC co-cultures. Cells were gated on the
single cell, live population. (B–G) Fractional labeling of aspartate (B–C), glutamate (D–E), and proline (F–G) in protein hydrolysates from sorted organoid
cancer cells (black) and PSCs (blue) after exposure of organoid co-cultures to U-13C-glucose for the indicated time. Cancer cells were derived from LSL-
Figure 4 continued on next page
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(Figure 5G). Cell populations were sorted from tumors, and labeling of amino acids was determined
in protein hydrolysates from each cell population as well as from protein obtained from the bulk
digested tumor (unsorted). In agreement with labeling patterns from organoid-co-cultures,
tdTomato+ cancer cells from PDAC tumors in mice had the highest M+3 protein aspartate labeling
in protein, as well as higher M+2 aspartate labeling (Figure 5H–I, Figure 5—source data 1). This
labeling pattern was also reflected in higher M+2 and M+3 labeling in glutamate but not in other
glucose-labeled amino acids in protein (Figure 5—figure supplement 1E–J, Figure 5—source data
1). Taken together, these data are consistent with increased pyruvate carboxylation, as well as
increased glucose oxidation via PDH, in the cancer cells relative to the stromal cell populations ana-
lyzed in PDAC tumors in vivo.
Pyruvate carboxylase expression in cancer cells is required for PDAC
tumor growth in vivo
To test whether PC is responsible for the observed pyruvate carboxylation activity and is functionally
important for cells to proliferate in organoid co-cultures and tumors, PC expression was disrupted in
murine PDAC cell lines, organoids, and PSCs using CRISPR/Cas9. First, CRISPRi was used to knock
down PC expression in a PDAC cancer cell line derived from KP-/-C mice (Figure 6—figure supple-
ment 1A; Horlbeck et al., 2016). The ratio of M+1 aspartate to M+1 pyruvate derived from 1-13C-
pyruvate or 3,4-13C-glucose has been used as a way to approximate pyruvate carboxylation activity
(Davidson et al., 2016). As expected, PC knockdown in these PDAC cells resulted in a decrease in
aspartate labeling from 1-13C-pyruvate and relative pyruvate carboxylation activity compared to con-
trol cells as assessed by the ratio of M+1 labeled aspartate to M+1 labeled pyruvate (Figure 6—fig-
ure supplement 1B–C), but did not affect proliferation in culture (Figure 6—figure supplement
1D). However, knockdown of PC in PDAC organoids reduced growth of these cells in organoid-PSC
co-cultures (Figure 6—figure supplement 1E–G). PC expression level and aspartate labeling from
1-13C-pyruvate were increased by exogenous PC expression in PDAC PC knockdown cells (Fig-
ure 6—figure supplement 1H–J). When transplanted subcutaneously, PDAC cell lines with PC
knockdown formed tumors that grew similarly to control cells (Figure 6—figure supplement 1K);
however, PC expression was similar or increased in the tumors formed from PC knockdown cells
compared to control tumors (Figure 6—figure supplement 1L). These data suggest that over time,
cells that grew into tumors were selected for reversal of PC knockdown and that PC is required for
PDAC tumor growth in vivo even though it is dispensable in culture, as has been observed previously
in lung cancer (Davidson et al., 2016; Fan et al., 2009; Sellers et al., 2015).
To further test the requirement for PC in PDAC tumors, we generated cancer cell clones with
complete CRISPR/Cas9 disruption of PC expression (Figure 6—figure supplement 1M–N). Similar
to knockdown experiments, loss of PC had no effect on proliferation of PDAC cells in culture
(Figure 6A), whereas loss of PC reduced the growth of organoid co-cultures (Figure 6B–C). CRISPR/
Cas9 was also used to knockout PC in PSCs, and despite loss of PC expression and reduced pyru-
vate carboxylation activity (Figure 6—figure supplement 2A–C), PC knockout PSCs retained the
Figure 4 continued
KrasG12D/+; Trp53fl/fl; Pdx1-Cre; LSL-tdTomato (KP-/-CT) mice. M+2 and M+3 isotopomers are shown as indicated. Each time point represents pooled
organoid co-culture samples from one 24-well plate in a representative experiment. (H) BFP fluorescence as measured by flow cytometry of a protein
synthesis reporter in the indicated cell type isolated from KP-/-CT PDAC organoid-PSC co-cultures over time following TMP administration. BFP
fluorescence is shown for cancer cells (black) and PSCs (blue). Mean +/- SD is shown. Data were normalized to no TMP controls. (I) Schematic
illustrating the 13C labeling patterns for 3,4-13C-glucose or 1-13C-pyruvate tracing. TCA cycle metabolites and aspartate are unlabeled from these
tracers if metabolized via PDH (left), but result in one carbon labeling (M+1) if metabolized via PC (right). (J) Fractional labeling of aspartate M+1 from
protein hydrolysates following three days of KP-/-CT organoid-PSC co-culture with 1-13C-pyruvate. The difference in aspartate M+1 labeling was
significant (p=0.0020) using an unpaired student’s t test. Mean +/- SD is shown. (K) Fractional labeling of aspartate M+1 from protein hydrolysates
following 3 days of KP-/-CT organoid-PSC co-culture with 3,4-13C-glucose. The difference in aspartate M+1 labeling was significant (p=0.0007) using an
unpaired student’s t test. Mean +/- SD is shown.
The online version of this article includes the following source data and figure supplement(s) for figure 4:
Source data 1. Isotope labeling of protein hydrolysates by U-13C- glucose in organoid-PSC co-cultures after sorting.
Figure supplement 1. PDAC cancer cells have higher pyruvate carboxylation activity than fibroblasts in organoid co-cultures.
Figure supplement 1—source data 1. Isotope labeling of protein hydrolysates by U-13C- glutamine in organoid-PSC co-cultures after sorting.
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Figure 5. PDAC cancer cells have higher pyruvate carboxylation activity in vivo. (A–B) Tumors from LSL-KrasG12D/+; Trp53fl/fl; Pdx1-Cre; LSL-tdTomato
(KP-/-CT) mice were stained with antibodies against RFP (red) and (A) a-SMA (green), a fibroblast marker, or (B) CK19 (green), a cancer cell marker. Scale
bars represent 25 mm. (C) A representative flow cytometry plot showing CD45 and tdTomato expression in cells derived from a PDAC tumor arising in
KP-/-CT mice. Cells were gated on the live population. (D) Expression of tdTomato was measured by qPCR in sorted cells from KP-/-CT PDAC tumors.
Figure 5 continued on next page
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ability to enhance PDAC organoid growth or growth of PDAC cancer cells as tumors in subcutane-
ous transplants, although the effect was reduced compared to sgControl PSCs (Figure 6—figure
supplement 2D–F). Consistent with a requirement for PC expression in cancer cells to form PDAC
tumors, PC-null cancer cells did not form tumors when transplanted into syngeneic mice subcutane-
ously or orthotopically (Figure 6D–E). However, surprisingly, PC-null cancer cells still displayed M+1
aspartate labeling from 1-13C-pyruvate with similar or only a slight decrease in pyruvate carboxyla-
tion activity compared to control cells (Figure 6F–G). Taken together, these data argue that loss of
PC in cancer cells can impact tumor growth, but another enzyme must also contribute to pyruvate
carboxylation activity in these cells.
Reversible malic enzyme 1 activity contributes to pyruvate
carboxylation activity in PDAC cells and is important for tumor growth
in vivo
A candidate for the pyruvate carboxylation activity observed in PC-null cells is malic enzyme, since
this enzyme catalyzes the interconversion of pyruvate and CO2 with malate, another 4-carbon TCA
cycle intermediate. Malic enzyme is typically assumed to catalyze malate decarboxylation as a source
of NADPH in cells (Cairns et al., 2011; Hosios and Vander Heiden, 2018), but has previously been
shown to be reversible and produce malate from pyruvate and CO2 in purified enzyme assays
(Ochoa et al., 1947; Ochoa et al., 1948). Thus, we tested whether malic enzyme activity could sus-
tain M+1 labeling of aspartate in PDAC cancer cells lacking PC by using CRISPR/Cas9 to knock out
malic enzyme 1 (ME1). After knockout of both PC and ME1 in PDAC cell lines, aspartate labeling
from 1-13C-pyruvate is virtually abolished, suggesting that ME1 activity can contribute to pyruvate
carboxylation activity in these cells (Figure 7A–B, Figure 7—figure supplement 1A). This aspartate
labeling was also increased after exogenous expression of ME1 in PC and ME1 double knockout
cells (Figure 7A–B). We used CRISPR/Cas9 to knockout or knockdown both PC and ME1 in organo-
ids, which also resulted in decreased M+1 aspartate labeling from 1-13C-pyruvate and decreased
pyruvate carboxylation activity (Figure 7—figure supplement 1B–D). We also used CRISPR/Cas9 to
knockout ME1 alone in PDAC cell lines and organoids (Figure 7—figure supplement 1E–H). Reduc-
tion or loss of ME1 alone in PDAC cell lines resulted in lower aspartate M+1 labeling and pyruvate
carboxylation activity from 1-13C-pyruvate (Figure 7—figure supplement 1F–K), further suggesting
a role for ME1 in anaplerosis. This aspartate labeling was also increased after exogenous expression
of ME1 in ME1 knockdown cells (Figure 7—figure supplement 1L–N). Interestingly, ME1 expression
in KP-/-C mouse and human PDAC tumors and organoids mimics that of PC in that it is more highly
Figure 5 continued
The difference in expression between cancer cells and whole tumor (p=0.0430), fibroblasts (p=0.0156), or hematopoietic cells (p=0.0119) was significant
based on unpaired, two-tailed student’s t-tests. Mean +/- SEM is shown. n = 6 mice. 18S was used as a housekeeping gene control. (E) Expression of a-
SMA was measured by qPCR in sorted cells from KP-/-CT PDAC tumors. The difference in expression between fibroblasts and whole tumor (p=0.0004),
cancer cells (p=0.0013), or hematopoietic cells (p=0.0003) was significant based on unpaired, two-tailed student’s t-tests. Mean +/- SEM is shown. n = 6
mice. 18S was used as a housekeeping gene control. (F) Expression of CD3e was measured by qPCR in sorted cells from KP-/-CT PDAC tumors. The
difference in expression between hematopoietic cells and whole tumor was not significant (p=0.3347), but the difference between hematopoietic cells
and cancer cells (p=0.0378) or fibroblasts (p=0.0379) was significant based on unpaired, two-tailed student’s t-tests. Mean +/- SEM is shown. n = 6
mice. 18S was used as a housekeeping gene control. (G) Fractional labeling of aspartate from protein hydrolysates from intact PDAC tumors following a
24 hr U-13C-glucose infusion at a rate of 30 mg/kg/min. n = 4. Mean +/- SEM is shown. (H) Fractional labeling of aspartate from protein hydrolysates
from the indicated sorted cell populations from tumors arising in KP-/-CT mice following a 24 hr U-13C-glucose infusion at a rate of 30 mg/kg/min. The
M+3 isotopomers are shown. The differences in M+3 aspartate labeling in cancer cells compared to fibroblasts (p=0.0413) and hematopoietic cells
(p=0.0005) were significant, and the difference between cancer cells and unsorted tumor cells (p=0.0612) was not significant based on unpaired, two-
tailed student’s t-tests. Mean +/- SEM is shown. n = 5 mice. (I) Fractional labeling of aspartate from protein hydrolysates from the indicated sorted cell
populations from tumors arising in KP-/-CT mice following a 24 hr U-13C-glucose infusion at a rate of 30 mg/kg/min. The M+2 isotopomers are shown.
The differences in M+2 aspartate labeling in cancer cells compared to fibroblasts (p=0.0309) and hematopoietic cells (p=0.0035) were significant, and
the difference between cancer cells and unsorted tumor cells (p=0.7444) was not significant based on unpaired, two-tailed student’s t-tests. Mean +/-
SEM is shown. n = 5 mice.
The online version of this article includes the following source data and figure supplement(s) for figure 5:
Source data 1. Isotope labeling of protein hydrolysates in mice with autochthonous PDAC tumors after 24 hr of U-13C- glucose infusion and sorting.
Figure supplement 1. PDAC cancer cells have higher pyruvate carboxylation activity in vivo.
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Figure 6. Pyruvate carboxylase in cancer cells is required for PDAC tumor growth in vivo. (A) Proliferation rate of AL1376 murine PDAC cells without
(sgControl) or with (sgPC) deletion in standard 2D culture. Mean +/- SD is shown. (B) Fluorescent images of murine PDAC cancer cell organoids
expressing tdTomato without (sgControl) or with (sgPC) deletion cultured in DMEM-pyruvate with 10% dialyzed FBS alone (top) or with murine PSCs
(bottom). (C) Quantification of tdTomato fluorescence from images in (B). Control organoids with PSCs had significantly higher tdTomato fluorescence
Figure 6 continued on next page
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expressed in cancer cells compared to stroma, suggesting that ME1 could also contribute to the
higher pyruvate carboxylation seen in cancer cells compared to PSCs (Figure 7C–E, Figure 7—fig-
ure supplement 2A–E).
We next assessed whether ME1 was essential for tumor and organoid growth. Similar to loss of
PC, loss of ME1 had minimal effect on cancer cell proliferation in monoculture (Figure 7F, Figure 7—
figure supplement 1F), but reduced growth of organoid co-cultures compared to controls
(Figure 7G–H, Figure 7—figure supplement 1E). Transplantation of ME1-null cancer cells in vivo
also resulted in reduced tumor growth (Figure 7I), consistent with published data (Son et al., 2013).
Taken together, these data argue that both PC and ME1 are important enzymes for PDAC cancer
cells in tumors and can contribute to the pyruvate carboxylation activity observed in pancreatic
cancer.
Discussion
Metabolism can differ between cancer cells in culture and tumors, and understanding how nutrients
are used by cancer cells in vivo has been an area of interest for developing cancer therapies. Tumor
metabolic phenotypes have been assumed to reflect the metabolism of cancer cells within a tumor;
however, in many tumors such as in PDAC, cancer cells are a minority cell population. Metabolic
interactions between cell types have been described in normal tissues (Be´langer et al., 2011), and
some metabolic phenotypes observed in cancer cells such as increased glucose utilization are also
prominent in other cell types including fibroblasts and immune cells that can be abundant in some
tumors (Lemons et al., 2010; Vincent et al., 2008; Zhao et al., 2019). Therefore, methods to
deconvolute which cell types in a tumor are responsible for observed tissue metabolic phenotypes
are needed.
We find that pancreatic tumors exhibit evidence of glucose metabolism, with carboxylation of glu-
cose-derived pyruvate being more active in cancer cells than in other tumor cell types. However,
because glucose will label both pyruvate and lactate, and these nutrients can be exchanged
between cell types, it cannot be concluded that the cancer cells necessarily derive TCA cycle metab-
olites directly from glucose in a cell autonomous manner. In fact, rapid exchange of labeled intracel-
lular and extracellular pyruvate and lactate among cell types is likely, making it difficult to address
the original cellular source of labeled TCA metabolites with these methods. Thus, while this
approach could be used to understand differential pathway use between cell types, in many cases it
will not be able to distinguish the exact source of carbon that labels metabolites in individual cells.
Another important caveat to interpreting labeling patterns in protein or other macromolecules in
cells within tissues is that labeling is unlikely to reach steady state, particularly for analysis of cells in
tissues in vivo. This failure to reach steady state means that differences in label delivery or uptake
could cause differences in biomass labeling even when the pathway involved in labeling is similarly
active in both cell types. Thus, controlling for variables such as biomass synthesis rates between cell
types can help with data interpretation. The ability to reach a pseudo-metabolic steady state facili-
tates interpretation of labeling data; however, this requires that both circulating nutrient levels and
labeling patterns are relatively constant (Buescher et al., 2015; Jang et al., 2018). Glucose infusion
rates and techniques can vary across studies (Davidson et al., 2016; Faubert et al., 2017;
Figure 6 continued
than sgPC organoids grown with PSCs (p=0.0171) based on an unpaired, two-tailed student’s t-test. Mean +/- SD is shown. (D) Growth of sgControl
(black) and sgPC (blue) AL1376 murine PDAC cells as tumors following subcutaneous transplantation into syngeneic Bl6 mice. The final tumor volume is
significantly greater in sgControl AL1376 cells compared to sgPC cells based on unpaired, two-tailed student’s t-tests (p<0.0001 to 0.0049). Mean +/-
SEM is shown. n = 6 for each group. (E) Growth of sgControl and sgPC AL1376 murine PDAC cells as tumors after orthotopic transplantation into the
pancreas of syngeneic Bl6 mice. Tumor weight was measured after 21 days and was significantly greater in mice transplanted with sgControl cells
based on an unpaired, two-tailed student’s t-test (p=0.0050). Mean +/- SEM is shown. n = 5 mice for each group. (F) Fractional labeling of aspartate in
sgControl and sgPC AL1376 murine PDAC cells after 24 hr of culture with 1-13C-pyruvate. Mean +/- SD is shown. (G) Aspartate M+1 isotopomer
labeling from (F) was normalized to pyruvate M+1 labeling as a surrogate for pyruvate carboxylation activity. Mean +/- SD is shown.
The online version of this article includes the following figure supplement(s) for figure 6:
Figure supplement 1. Pyruvate carboxylase in cancer cells is required for PDAC tumor growth in vivo.
Figure supplement 2. Pyruvate carboxylase knockout PSCs retain ability to enhance PDAC growth.
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Figure 7. Malic enzyme 1 contributes to pyruvate carboxylation activity in PDAC cells and is important for tumor growth. (A–B) CRISPR/Cas9 was used
to disrupt PC and/or ME1 as indicated in AL1376 murine PDAC cells. (A) Fractional labeling of M+1 aspartate following culture of the indicated cells for
24 hr in media containing 1-13C-pyruvate. M+1 aspartate labeling was significantly decreased in double knockout cells compared to control cells
(p=0.0012, 0.0001, and 0.0131) or to double knockout cells with exogenous ME1 expression (ME rescue) (p=0.0006) based on unpaired, two-tailed
student’s t-tests. Mean +/- SD is shown. (B) Aspartate M+1 isotopomer labeling was normalized to pyruvate M+1 labeling as a surrogate for pyruvate
carboxylation activity following 24 hr of 1-13C-pyruvate tracing. Pyruvate carboxylation activity was significantly decreased in double knockout cells
compared to control cell lines (p=0.0004, 0.0002, and 0.0100) or to double knockout cells with exogenous ME1 expression (ME rescue) (p<0.0001) based
on unpaired, two-tailed student’s t-tests. Mean +/- SD is shown. (C) Sections from tumors arising in LSL-KrasG12D/+; Trp53fl/fl; Pdx1-Cre (KP-/-C) mice
were stained with an antibody against ME1. Scale bar represents 100 mm. (D) Expression of ME1 was measured by qPCR in the indicated cells sorted
from tumors arising in KP-/-C mice. The expression of ME1 was not significantly different in sorted cancer cells compared to the whole tumor
Figure 7 continued on next page
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Hui et al., 2017; Ma et al., 2019; Marin-Valencia et al., 2012), and these differences may affect
whether circulating nutrient levels are constant. While this may be one reason why differences in
labeling were observed across PDAC models evaluated in this study, additional factors such as
tumor initiation and growth rates, cells of origin, p53 status, and different composition of cancer and
stromal cells are known to exist as well (Rosenfeldt et al., 2013; Vennin et al., 2019).
While we did not directly assess the effects of cell sorting on metabolite levels or labeling in this
study, we observed that for some metabolites, their levels and/or labeling patterns are not stable
over the time needed to sort cells. However, the labeling patterns of some metabolites were main-
tained despite changes in levels, and might still be used to derive information about cell-specific
metabolism, particularly when appropriate controls and orthogonal evidence support the
conclusions.
We find that whether cells are grown in 2D cultures, in 3D organoid co-culture with PSCs, or as
orthotopic or subcutaneous tumors impacts whether pyruvate carboxylation is important for prolifer-
ation, with the organoid and tumor models showing a similar dependency on this activity. Tumor
organoid-stromal co-cultures represent a tractable model for metabolic characterization, and thus
may be useful for exploration of other symbiotic metabolic relationships between pancreatic cancer
cells and fibroblasts. However, while the difference in M+3 aspartate labeling seen in vivo was reca-
pitulated by organoid-fibroblast co-cultures, other differences such as higher M+2 aspartate and glu-
tamate labeling observed in vivo were not observed in the co-culture model. Therefore, some
aspects of cell type-specific metabolism are not recapitulated even in co-culture organoid systems.
We find that PC and ME1 expression in cancer cells are both important for PDAC tumor growth
in vivo. A dependence on pyruvate carboxylation seems to be a characteristic of both PDAC and
lung tumors in vivo that is not prominent in standard cell culture systems (Christen et al., 2016;
Davidson et al., 2016; Fan et al., 2009; Hensley et al., 2016; Sellers et al., 2015). Why this is the
case is not known, but PC is an important anaplerotic pathway for the TCA cycle, contributing to
biosynthesis of macromolecules such as protein, nucleotides, and lipids in cancer cells. Glucose
metabolism and increased glucose uptake have been shown to be important for biosynthesis in
PDAC tumors (Santana-Codina et al., 2018; Ying et al., 2012), but it has also been suggested that
some PDAC tumors rely less on glucose for fuel and instead on alternative nutrient sources such as
circulating lactate and glutamine (Hui et al., 2017), or alanine from stromal autophagy (Sousa et al.,
2016). We did not observe differences in protein alanine labeling from glucose in either PSCs or
organoids, although it remains possible the cells differentially utilize alanine acquired from a source
other than glucose. For example, macropinocytosis to catabolize extracellular protein can be an
important source of amino acids for cells in PDAC tumors (Commisso et al., 2013; Davidson et al.,
2017). Nevertheless, the findings that PDAC tumors are FDG-PET positive (Nguyen et al., 2011;
Parikh et al., 2015; Yeh et al., 2018) and that levels of glucose are depleted in tumor interstitial
fluid relative to plasma in PDAC mouse models (Sullivan et al., 2019), are consistent with glucose
being consumed by at least some cell types within the tumor.
Figure 7 continued
(p=0.1114), but was significantly higher in sorted cancer cells compared to fibroblasts (p=0.0009) based on unpaired, two-tailed student’s t-tests. Mean
+/- SEM is shown. 36B4 was used as a housekeeping gene control. (E) Representative image from a human pancreatic tumor tissue microarray stained
with an antibody against ME1. Scale bar represents 100 mm. (F) Proliferation rate of sgControl and sgME1 AL1376 murine PDAC cells in standard 2D
culture. (G) Quantification of tdTomato fluorescence from images of sgControl or sgME1 PDAC cancer cell organoids isolated from KP-/-CT tumors
cultured in DMEM-pyruvate with 10% dialyzed FBS alone or with murine PSCs. sgControl organoids with PSCs trended towards higher tdTomato
fluorescence compared to sgME1 organoids with PSCs (p=0.0579) but was not significant based on an unpaired, two-tailed student’s t-test. Mean +/-
SD is shown. The sgControl data are also shown in Figure 6B–C. (H) Fluorescent images of sgControl or sgME1 PDAC cancer cell organoids cultured
DMEM-pyruvate with 10% dialyzed FBS alone (top) or with murine PSCs (bottom). The sgControl images are also shown in Figure 6B–C. (I) Growth of
sgControl (black) and sgME1 (blue) AL1376 murine PDAC cells as tumors following subcutaneous transplantation into syngeneic B6 mice. The final
tumor volume is significantly greater in sgControl AL1376 cells compared to sgME1 cells based on unpaired, two-tailed student’s t-tests (p<0.0001 to
0.0017). Mean +/- SEM is shown. n = 6 for each group.
The online version of this article includes the following figure supplement(s) for figure 7:
Figure supplement 1. Malic enzyme 1 contributes to pyruvate carboxylation activity in PDAC cells and is important for tumor growth.
Figure supplement 2. Expression of ME1 in a human PDAC tissue microarray and in murine organoids and stroma.
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Glutamine is also a source of TCA anaplerotic carbon that may contribute to biosynthesis differ-
entially between cancer cells and stroma. Previous work has suggested that utilization of ME1 to
produce pyruvate from glutamine can be important for PDAC cells to maintain redox balance, spe-
cifically via NADPH generation in vitro (Son et al., 2013), and that glutamine can be a major contrib-
utor to TCA metabolites in PDAC tumors (Hui et al., 2017). A potential role for malic enzyme in
pyruvate carboxylation suggests use of this enzyme to produce malate could be another pathway
for TCA cycle anaplerosis. Of note, this reaction would require NADPH, and may be more favored in
cancer cells that exhibit a reduced redox state (Hosios and Vander Heiden, 2018). Furthermore,
other pathways produce NADPH in cancer cells, including the pentose phosphate pathway, the one-
carbon cycle, or isocitrate dehydrogenase (Chen et al., 2019). We also considered phosphoenolpyr-
uvate carboxykinase (PEPCK) or malic enzymes 2 and 3 as possible contributors to pyruvate carbox-
ylation activity, although these reactions are less energetically favorable in the reverse direction in
comparison to malic enzyme 1; malic enzyme 1 is cytosolic, which is thought to be a more reducing
environment than the mitochondria where malic enzymes 2 and 3 are localized (Hu et al., 2008). We
did not see evidence for differential glutamine utilization in our organoid-PSC co-cultures, and
PDAC tumors are resistant to glutaminase inhibitors (Biancur et al., 2017), but further work is
needed to assess how glutamine metabolism and other anaplerotic pathways might be differentially
active in cancer cells and non-cancer cells in PDAC tumors.
In pancreatic b-cells, PC and ME are thought to be part of a coordinated metabolic cycle that reg-
ulates insulin secretion (Pongratz et al., 2007). In this pyruvate cycle, ME1 generates NADPH and
produces pyruvate from malate in the cytosol, which can then be used by PC to generate oxaloace-
tate in the mitochondria (Pongratz et al., 2007). While loss of ME activity might be expected to
impact pyruvate carboxylation activity when both enzymes are present, the fact that residual pyru-
vate carboxylation activity is observed in the absence of PC, and that this is lost upon ME1 disrup-
tion argues that PC and ME may have redundant metabolic functions under some conditions.
Surprisingly, isotope labeling in cells with loss of ME1 alone showed a larger decrease in labeling
consistent with pyruvate carboxylation than was observed with PC knocked out and ME1 left intact.
However, these data should not be used to conclude that flux through ME1 is higher than PC, partic-
ularly in cells where both enzymes are expressed and pyruvate cycling can occur. PC and ME1 are
each essential for pancreatic tumors in vivo, despite a possible redundancy in pyruvate carboxylation
activity. This may be because pyruvate cycling is important for tumor growth, or the need for anaple-
rosis to support tumor growth is more constrained in tumors than in cell culture. Indeed, a depen-
dence on pyruvate carboxylation seems to be a characteristic of tumors in vivo that is not observed
in culture across many cancer models (Christen et al., 2016; Davidson et al., 2016; Fan et al.,
2009; Hensley et al., 2016; Sellers et al., 2015).
PC has been targeted with antisense oligonucleotides (Kumashiro et al., 2013) and relatively
non-specific chemical inhibitors (Bahl et al., 1997; Zeczycki et al., 2010); however, inhibiting PC
may have deleterious effects on whole body metabolism by interfering with gluconeogenesis or glu-
cose-stimulated insulin secretion. Whether malic enzyme can compensate sufficiently for PC inhibi-
tion in those tissues to allow therapeutic targeting, or if malic enzyme is a viable alternative target,
remains to be determined. Nevertheless, our data suggest that stable isotope tracing into macromo-
lecules can be utilized to deconvolute complex tracing patterns in mammalian tissues and identify
increased pathway activity in a particular cell type. Understanding the metabolic similarities and dif-
ferences between cancer cells and stroma within PDAC and other tumors will be important in further
delineating cancer-specific dependencies.
Materials and methods
Key resources table
Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Strain, strain
background
(Mus musculus)
C57Bl6/J Jax Cat# JAX:000664,
RRID:IMSR_JAX:000664
Used for cell
line transplantation
Continued on next page
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Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Genetic Reagent
(M. musculus)
LSL-KrasG12D/+
Trp53flox/flox
Pdx-1-Cre
LSL-tdTomato;
KP-/-CT
Bardeesy et al., 2006
PMID:16585505
Mice from a mixed
129/Sv and C57Bl6/J
genetic background
as well as pure
C57Bl6/J mice were
used. Both sexes of
mice were included
in experiments.
Genetic Reagent
(M. musculus)
LSL-KrasG12D/+
Trp53R172H/+
Pdx-1-Cre
LSL-tdTomato;
KPCT
Hingorani et al., 2005
PMID:15894267
Mice from a mixed
129/Sv and C57Bl6/J
genetic background
as well as pure
C57Bl6/J mice were
used. Both sexes of
mice were included
in experiments.
Genetic Reagent
(M. musculus)
b-actin-GFP Jax Cat# JAX:006567,
RRID:IMSR_JAX:006567
PSCs were isolated
from b-actin-GFP
mice in a C57Bl6/J
background.
Cell line
(M. musculus)
PSC Danai et al., 2018
PMID:29925948
Isolated from b-actin-GFP mice in a C57Bl6/J
background (Jax
006567). PSCs were
immortalized with TERT
and SV40 largeT
after several passages.
Cell line
(M. musculus)
AL1376 Sullivan et al., 2018
PMID:29941931
Isolated from KP-/-CT
mouse PDAC tumor
in a C57Bl6/J
background.
Cell line
(M. musculus)
Organoid This paper Isolated from KP-/-CT
mouse PDAC tumor
in a C57Bl6/J
background
Biological sample
(Homo sapiens)
Human pancreatic
cancer tissue
microarray
Biomax PA961e
Antibody a-SMA (mouse
monoclonal)
Sigma Cat# F3777,
RRID:AB_476977
IF (1:500)
Antibody CK19
(Rabbit
monoclonal)
Abcam Cat# ab133496,
RRID:AB_ 11155282
IF (1:100)
Antibody tdTomato
(Rabbit
polyclonal)
Rockland Cat# 600-401-379,
RRID:AB_2209751
IF (1:500)
Antibody Pyruvate
Carboxylase
(Rabbit
polyclonal)
Santa Cruz Cat# sc-67021,
RRID:AB_2283532
IHC (1:50)
Antibody Pyruvate
Carboxylase
(Mouse
monoclonal)
Santa Cruz Cat# sc-271493,
RRID:AB_10649369
WB (1:100)
Antibody Malic Enzyme 1
(Rabbit polyclonal)
Proteintech Cat# 16619-1-AP,
RRID:AB_2143821
IHC (1:200)
WB (1:250)
Antibody b-actin (Rabbit
monoclonal)
Cell Signaling
Technologies
Cat# 8457,
RRID:AB_10950489
WB (1:10,000)
Antibody CD16/CD32
(Rat monoclonal)
Thermo Fisher Cat# 14-0161-82,
RRID:AB_467133
FACS (10uL)
Continued on next page
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Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Antibody CD45-APC-Cy7
(Rat monoclonal)
BD Cat# 557659,
RRID:AB_396774
FACS (1:100)
Antibody Puromycin
(Mouse
monoclonal)
Sigma MABE343 WB (1:25,000)
Antibody Vinculin
(Mouse
monoclonal)
Abcam Cat# ab18058,
RRID:AB_444215
WB (1:1000)
Commercial
Assay or Kit
Protein A
Antibody
Purification Kit
Sigma PURE1A
Commercial
Assay or Kit
RNAqueous-Micro
Total RNA
Isolation Kit
Life
Technologies
AM1931
Commercial
Assay or Kit
iScript cDNA
Synthesis Kit
Bio-Rad
Laboratories
1708890
Commercial
Assay or Kit
Pierce BCA
Protein Assay Kit
Pierce 23225
Commercial
Assay or Kit
Amaxa Basic
Nucleofector Kit
for Primary
Mammalian
Epithelial Cells
Amaxa VPI-1005
Recombinant
DNA Reagent
pUSPmNG
(plasmid)
Li et al., 2019
PMID:31694929
U6 sgRNA PGK with
mNeonGreen to
express sgRNAs for
PC and ME1 double
knockout cell lines
Recombinant
DNA Reagent
LentiCRISPRv2
(plasmid)
Sanjana et al., 2014
PMID:25075903
Lentiviral construct to
create PC and
ME1 knockout cells
Recombinant
DNA Reagent
Modified
LentiCRISPRv2
(plasmid)
Horlbeck et al., 2016
PMID:27661255
Modified dCas9-KRAB
fusion protein to
create PC and ME1
knockdown cells
Recombinant
DNA Reagent
pLV-Hygro-EFS
(plasmid)
Vectorbuilder Custom lentiviral
construct for re-
expressing PC or ME1
cDNA under a
CMV promoter
Peptide,
recombinant
protein
EGF Thermo Fisher PMG8041
Peptide,
recombinant
protein
FGF Peprotech 100-26
Peptide,
recombinant
protein
Gastrin I TOCRIS 3006
Peptide,
recombinant
protein
Noggin Peprotech 250-38
Chemical
compound,
drug
Collagenase I Worthington
Biochemical
LS004194
Continued on next page
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Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Chemical
compound,
drug
Collagenase XI Sigma C9407
Chemical
compound,
drug
Collagenase P Sigma 11213865001
Chemical
compound,
drug
Dispase II Roche 04942078001
Chemical
compound,
drug
TrypLE Express Thermo Fisher 12605-010
Chemical
compound,
drug
DNAse I
Type II
Sigma D4527
Chemical
compound,
drug
DNAse I
Type IV
Sigma D5025
Chemical
compound,
drug
GlutaMAX Thermo Fisher 35050
Chemical
compound,
drug
HEPES Thermo Fisher 15630
Chemical
compound,
drug
TGF-b inhibitor
A-83-01
TOCRIS 2939
Chemical
compound,
drug
Rho Kinase
Inhibitor Y-27632
Sigma Y0503
Chemical
compound,
drug
N-Acetylcysteine
(NAC)
Sigma A9165
Chemical
compound,
drug
Nicotinamide Sigma N0636
Chemical
compound,
drug
B-27 supplement Thermo Fisher 17504
Chemical
compound,
drug
Methoxamine
(MOX) reagent
ThermoFisher TS-45950
Chemical
compound,
drug
N–methyl–N–(tert–
butyldimethylsilyl)
trifluoroacetamide +
1% tert–
Butyldimethylchlorosilane
Sigma 375934
Chemical
compound,
drug
Pyridine Sigma 270407
Chemical
compound,
drug
Nycodenz VWR 100356-726
Chemical
compound,
drug
Sulforhodamine B Sigma 230162
Continued on next page
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Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Chemical
compound,
drug
SYBR Green
Master Mix
Sigma L6544
Software,
algorithm
Prism GraphPad Statistical analysis
and graphing
Software,
algorithm
FlowJo BD Flow cytometry
data analysis
Other SYTOX Red
Dead Cell Stain
Life
Technologies
S34859 FACS (1:1000)
Other Advanced
DMEM/F12
Thermo Fisher 12634
Other DMEM without
pyruvate
Corning 10-017-CV
Other GBSS Sigma G9779
Other Growth factor
reduced (GFR)
matrigel
Corning 356231
Other Plastic coverslips Thermo 174985
Other Flow cytometry
staining buffer
Thermo Fisher 00-4222-57
Mouse models
All animal studies were approved by the MIT Committee on Animal Care under protocol #0119-001-
22. For autochthonous models, LSL-KrasG12D/+; Trp53flox/flox; Pdx1-Cre; LSL-tdTomato (KP-/-CT)
(Bardeesy et al., 2006) and LSL-KrasG12D/+; Trp53R172H/+; Pdx1-Cre; LSL-tdTomato (KPCT)
(Hingorani et al., 2005), mice from a mixed 129/Sv and C57Bl6/J genetic background as well as
pure C57Bl6/J mice were used. C57Bl6/J mice were used for allografts. Both sexes of mice were
included in experiments. Animals were housed under a 12 hr light and 12 hr dark cycle, and
cohoused with littermates with ad libitum access to water and food unless otherwise stated.
Glucose infusion
Infusion of U-13C-glucose (Cambridge Isotope Laboratories) was performed as previously described
(Davidson et al., 2016). Surgery was performed to implant a catheter into the jugular vein of animals
3–4 days prior to infusion. For 4–6 hr infusions, mice were fasted for 4 hr prior to beginning the infu-
sion. For 24 hr infusions, mice were not fasted prior to infusion. Infusions were performed in con-
scious, free-moving animals for 4 or 24 hr at a rate of 30 mg/kg/min. For 6 hr infusions, each animal,
regardless of body weight, was infused with a fixed volume of 300 ml of a 500 mg/ml glucose solu-
tion over 6 hr, which is an infusion rate of 0.4 mg/min.
Tumors were either digested for FACS or rapidly frozen using a Biosqueezer (BioSpec Products)
and stored at  80˚C prior to metabolite extraction.
Isotope labeling experiments
100,000 adherent cells were plated in six-well plates, or organoids and organoid-PSC co-cultures
were plated on plastic coverslips (Thermo 174985) in 24-well plates. The following day, the cells
were washed three times with PBS and then isotope-labeled media was added for the specified
length of time (24–72 hr). For U-13C-glucose or 3,4-13C-glucose tracing, DMEM without glucose and
pyruvate was used, supplemented with 25 mM U-13C-glucose or 3,4-13C-glucose, 10% dialyzed FBS,
and penicillin-streptomycin. For 1-13C-pyruvate tracing, DMEM with glucose and without pyruvate
was used, adding 2 mM 1-13C-pyruvate and supplementing with 10% dialyzed FBS and penicillin-
streptomycin.
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Polar metabolite extraction
Adherent cells were washed once with ice-cold saline on ice and then extracted with a 5:3:5 ratio of
ice-cold HPLC-grade methanol:water:chloroform. Mouse tissue or coverslips containing organoids
and organoid-PSC co-cultures were washed once with saline prior to extraction. Tissue or matrigel
domes containing the organoids and organoid-PSC co-cultures were then rapidly frozen using a Bio-
squeezer (BioSpec Products) and stored at  80˚C prior to metabolite extraction. Snap frozen tissues
or organoids were extracted with a 5:3:5 ratio of ice-cold HPLC-grade methanol:water:chloroform.
For mouse plasma, 10 mL of plasma was extracted with 600 mL ice-cold methanol. All samples were
vortexed for 10 min at 4˚C followed by centrifugation for 5 min at maximum speed on a tabletop
centrifuge (~21,000 xg) at 4˚C. An equal volume of the aqueous phase of each sample was then
dried under nitrogen gas and frozen at  80˚C until analysis. For organoid samples, two rounds of
extraction were done to eliminate excess protein from matrigel.
Protein hydrolysis
Acid hydrolysis of protein was performed as described previously (Mayers et al., 2016;
Sullivan et al., 2018). Frozen tissue or cell pellets were boiled for 24 hr at 100˚C in 500 mL (cell pel-
lets)  1 mL (tissue) 6M HCl for amino acid analysis (Sigma 84429). 50 mL (tissue)  100 mL (cell pellets)
of HCl solution was then dried under nitrogen gas while heating at 80˚C. Dried hydrolysates were
stored at  80˚C until derivatization.
GC-MS analysis
Polar metabolites were analyzed as described previously (Lewis et al., 2014). Dried free metabolite
extracts were dissolved in 16 mL methoxamine (MOX) reagent (ThermoFisher TS-45950) and incu-
bated at 37˚C for 90 min followed by addition of 20 mL N–methyl–N–(tert–butyldimethylsilyl)trifluor-
oacetamide + 1% tert–Butyldimethylchlorosilane (Sigma 375934) and incubated at 60˚C for 1 hr.
Dried protein hydrolysates were re-dissolved in 16 mL HPLC grade pyridine (Sigma 270407) prior to
derivatization with 20 mL N–methyl–N–(tert–butyldimethylsilyl)trifluoroacetamide + 1% tert–Butyldi-
methylchlorosilane (Sigma 375934) at 60˚C for 1 hr. Following derivatization, samples were analyzed
using a DB-35MS column (Agilent Technologies) in an Agilent 7890 gas chromatograph coupled to
an Agilent 5975C mass spectrometer. Helium was used as the carrier gas at a flow rate of 1.2 mL/
min. One microliter of sample was injected at 270˚C. After injection, the GC oven was held at 100˚C
for 1 min and increased to 300˚C at 3.5 ˚C/min. The oven was then ramped to 320˚C at 20 ˚C/min
and held for 5 min. at this 320˚C. The MS system operated under electron impact ionization at 70 eV
and the MS source and quadrupole were held at 230˚C and 150˚C, respectively. The detector was
used in scanning mode, and the scanned ion range was 100–650 m/z. Data were corrected for natu-
ral isotope abundance.
Adherent cell culture
Cell lines were cultured in DMEM (Corning 10–013-CV) supplemented with 10% fetal bovine serum
and penicillin-streptomycin. Cell lines were regularly tested for mycoplasma contamination using the
MycoAlert Plus kit (Lonza) or the Mycoprobe Mycoplasma Detection Kit (R and D Systems). PSCs
were isolated from b-actin-GFP mice in a C57Bl6/J background (006567) as previously described
(Apte, 2011; Danai et al., 2018): 3 mL of 1.3 mg/mL cold collagenase P (Sigma 11213865001) and
0.01 mg/mL DNAse (Sigma D5025) in GBSS (Sigma G9779) were injected into the pancreas. The tis-
sue was then placed into 2 mL of collagenase P solution on ice. Cells were then placed in a 37˚C
water bath for 15 min. The digested pancreas was filtered through a 250 mm strainer and washed
with GBSS with 0.3% BSA. A gradient was created by resuspending the cells in Nycodenz (VWR
100356–726) and layering in GBSS with 0.3% BSA. Cells were then centrifuged at 1300 x g for 20
min at 4˚C. The layer containing PSCs was removed, filtered through a 70 mm strainer, washed in
GBSS with 0.3% BSA, and plated for cell culture in DMEM with 10% FBS and penicillin-streptomycin.
PSCs were immortalized with TERT and SV40 largeT after several passages.
Organoid culture
Organoids were isolated from mice bearing PDAC tumors and cultured as previously described
(Boj et al., 2015). Tumors were minced and digested overnight with collagenase XI (Sigma C9407)
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and dispase II (Roche 04942078001) and embedded in 50 mL domes of growth factor reduced (GFR)
matrigel (Corning 356231) covered with 500 mL of complete media. Complete media consisted of
Advanced DMEM/F12 (Thermo Fisher 12634) containing GlutaMAX (Thermo Fisher 35050), penicil-
lin-streptomycin, HEPES (Thermo Fisher 15630), 0.5 mM TGF-b inhibitor A-83–01 (TOCRIS 2939),
0.05 mg/mL EGF (Thermo Fisher PMG8041), 0.1 mg/mL FGF (Peprotech 100–26), 0.01 mM Gastrin I
(TOCRIS 3006), 0.1 mg/mL Noggin (Peprotech 250–38), 10.5 mM Rho Kinase Inhibitor Y-27632 (Sigma
Y0503), 1.25 mM N-Acetylcysteine (NAC) (Sigma A9165), 10 mM Nicotinamide (Sigma N0636), 1X
B-27 supplement (Thermo Fisher 17504), and 1 mg/mL R-spondin. R-spondin was purified from 293 T
cells engineered to produce it using a Protein A Antibody Purification Kit (Sigma PURE1A). Organo-
ids were grown in complete media when passaging. For organoid-PSC co-culture experiments, co-
cultures were grown in DMEM without pyruvate (Corning 10–017-CV) supplemented with 10% dia-
lyzed FBS and penicillin-streptomycin. Organoids were regularly tested for mycoplasma contamina-
tion using the MycoAlert Plus kit (Lonza) or the Mycoprobe Mycoplasma Detection Kit (R and D
Systems).
Organoids were digested to single cells by incubating with 2 mg/mL dispase in Advanced
DMEM/F12 with penicillin-streptomycin, HEPES, and GlutaMAX at 37˚C for 20 min. Organoids were
then triturated with a fire-polished glass pipette and enzymatically digested with 1 mL TrypLE
Express (Thermo Fisher 12605–010) for 10 min rotating at 37˚C, followed by addition of 1 mL of dis-
pase containing media and 10 mL of 10 mg/mL DNAse (Sigma 4527) and digested rotating at 37˚C
for 20 min or until single cells were visible under a microscope. Cells were counted and plated in
GFR matrigel at a concentration of 2000 cells/well.
Proliferation assays
50,000 cells were seeded in six-well plates in 2 mL DMEM with 10%FBS and penicillin-streptomycin.
The next day, cells were counted for day 0 and media was changed on remaining cells. 8 mL of
media was added and cells were left to proliferate for 3 days. On day 3, cells were trypsinized and
counted. Alternatively, proliferation was measured using sulforhodamine B staining as previously
described (Vichai and Kirtikara, 2006). Cells were fixed on day 0 and day 3 with 500 ml of 10% tri-
chloroacetic acid (Sigma T9159) in 1 mL media and incubated at 4˚C for at least 1 hr. Plates were
washed under running water and cells were stained with 1 mL sulforhodamine B (Sigma 230162) and
incubated at room temperature for 30 min. Dye was removed and cells were washed three times
with 1% acetic acid. Plates were then dried and 1 mL of 10 mM Tris pH 10.5 was added to each well
to solubilize the dye. 100 mL of each sample was then transferred to a 96-well plate and absorbance
was measured at 510 nm on a microplate reader.
Protein synthesis assays
A fluorescent reporter in which BFP is fused to an unstable E. coli dihydrofolate reductase (DHFR)
degron domain which is stabilized by trimethoprim (Han et al., 2014) was used to determine global
protein synthesis rate as previously described (Darnell et al., 2018). Briefly, PDAC/PSC cell lines and
PDAC organoids expressing the reporter were generated by lentiviral transduction and puromycin
selection followed by flow cytometry-based sorting for populations that were BFP-positive after
TMP addition for 24–48 hr. For each experiment, the reporter protein was stabilized upon addition
of 10 uM trimethoprim (TMP) and fluorescence accumulation was measured in cells or organoids by
flow cytometry over several time points within 12 hr of TMP addition. Data were normalized to no
TMP controls. Puromycin incorporation assays were performed as previously described
(Schmidt et al., 2009). 10 mg/mL puromycin was spiked into the medium of cells grown in 6 cm
plates. Plates were kept at 37˚C for indicated pulse times (spanning 2.5 to 20 min). As a negative
control, 100 mg/mL cycloheximide was added to a plate of cells for 45 min before the addition of
puromycin. At the end of the pulse, plates were washed once with ice cold PBS on ice and flash fro-
zen in liquid nitrogen. Cells were harvested from frozen plates by scraping into RIPA buffer contain-
ing cOmplete Mini EDTA-free Protease Inhibitor Cocktail (Roche 11836170001) and PhosSTOP
Phosphatase Inhibitor Cocktail Tablets (Roche 04906845001) and protein concentration was quanti-
fied using the Pierce BCA Protein Assay Kit (Pierce 23225). 2 mL of lysate (approximately 2 mg) was
spotted directly onto 0.2 mm nitrocellulose membranes and blotted with primary antibodies against
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puromycin (Sigma MABE343 1:25,000 dilution) and vinculin (Abcam ab18058, 1:1000 dilution) as a
control.
Generation of PC and ME1 knockdown and knockout cells
CRISPRi knockdown cell lines of PC and ME1 were generated by transfecting cells expressing modi-
fied dCas9-KRAB fusion protein, as previously described (Horlbeck et al., 2016). The target sequen-
ces used for PC sgRNAs were (PC1- GCGGCGGCCACGGCTAGAGG, PC2- G
TGGAGGCAGGGGCCGTCAG), the sequence for non-targeting control was GCGACTAGCGCCA
TGAGCGG, and the target sequence of ME1 sgRNA was GCCGCAGTGGCCTCCCGGGT. After
transfection, cells were selected under 5 ug/ml puromycin. Rescue of CRISPRi knockdown cell lines
of PC was performed by re-expressing the cDNA of the rescued gene under a CMV promoter using
a custom lentiviral construct generated on VectorBuilder and selected in 500 ug/ml blasticidin.
CRISPR knockout cell lines for PC and ME1 were generated using the LentiCRISPRv2 system, as pre-
viously described (Sanjana et al., 2014), with guides against the target sequence 5’ CGGCA
TGCGGGTCGTGCATA 3’ for PC and 5’ GTTTGGCATTCCGGAAGCCA 3’ for ME1. After transfec-
tion, cells were selected under 5 mg/ml of puromycin, single-cell cloned, and knockout validation
performed using western blot. For organoids, the same vector systems and guide sequences were
used. Organoids were transfected with concentrated virus by spinfection for 45 min at room temper-
ature. For CRISPR knockout organoids, organoid cultures were selected under 5 mg/ml of puromycin,
digested to single cells, and then single organoids were picked, expanded, and validated using
western blot.
Double knockout cell lines for PC and ME1 were generated using pUSPmNG (U6 sgRNA PGK
with mNeonGreen, Li et al., 2019) incorporated into cells via electroporation (Amaxa VPI-1005), and
selected by FACS using NeonGreen expression. For organoids, double knockout organoids were
generated using the LentiCRISPRv2 system and spinfected for 45 min at room temperature. After
transfection, cells were selected under 500 ug/ml of blasticidin, digested to single cells, and then sin-
gle organoids were picked, expanded, and validated using western blot.
Flow cytometry
Tumors were dissected, minced, and digested rotating for 30 min at 37˚C with 1 mg/mL Collagenase
I (Worthington Biochemical LS004194), 3 mg/mL Dispase II (Roche 04942078001), and 0.1 mg/mL
DNase I (Sigma D4527) in PBS. Following digestion, cells were incubated with EDTA to 10 mM at
room temperature for 5 min. Cells were then filtered through a 70 mm strainer and washed twice
with PBS. Single cell suspensions were resuspended in flow cytometry staining buffer (Thermo Fisher
00-4222-57) and first stained with 10 mL of CD16/CD32 monoclonal antibody (Thermo Fisher 14-
0161-82) for 15 min to block Fc receptors and then stained using with antibodies to CD45-APC-Cy7
(BD 557659) at 1:100 dilution followed by SYTOX Red Dead Cell Stain (Life Technologies S34859) at
1:1000 dilution to visualize dead cells. All antibodies were incubated for 15–20 min on ice and then
washed. Cell sorting was performed with a BD FACS Aria and data was analyzed with FlowJo Soft-
ware (BD).
Tumor transplantation
100,000 PDAC cells or 100,000 PDAC cells plus 100,000 PSCs in 100 mL PBS were transplanted sub-
cutaneously into the flanks of C57BL/6J mice (000664). Tumors were measured using calipers and
volume was calculated using the formula V = (p/6)(L*W2).
For orthotopic transplants, 100,000 PDAC cells in 50 mL PBS were transplanted into the pancreas
of C57BL/6J mice (000664) as previously described (Mayers et al., 2014).
Immunofluorescence
Tumors were fixed in 4% paraformaldehyde (PFA) rotating overnight at 4˚C followed by incubation
in 30% sucrose in PBS rotating overnight at 4˚C. Tumors were then embedded in optimal cutting
temperature (OCT) compound and stored at  80˚C until sectioning. Sections were stained with anti-
bodies against a-SMA (Sigma F3777, 1:500 dilution), CK19 (Abcam ab133496 1:100), and tdTomato
(Rockland 600-401-379, 1:500 dilution) using DAPI as a nuclear stain.
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Immunohistochemistry
Sections from formalin fixed paraffin embedded mouse tissue or a human pancreatic cancer tissue
microarray (Biomax PA961e) were stained with antibodies against PC (Santa Cruz sc-67021, 1:50
dilution) or ME1 (Proteintech 16619–1-AP, 1:200 dilution). The human pancreatic cancer tissue
microarray was scored independently by a pathologist (O.H.Y.), and assigned scores of 0–4 for both
staining intensity and percent of cells positive for expression of the indicated protein.
qPCR
RNA was isolated from cells using the RNAqueous-Micro Total RNA Isolation Kit (Life Technologies
AM1931) and cDNA was made using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories 1708890).
qPCR reactions were performed using SYBR Green Master Mix (Sigma L6544) and primers for pyru-
vate carboxylase (Forward: 5’- GGG ATG CCC ACC AGT CAC T  3’, Reverse: 5’- CAT AGG GCG
CAA TCT TTT TGA  3’), malic enzyme 1 (Forward: 5’- TGT GGG AAC AGA AAA TGA GGA GTT
 3’, Reverse: 5’- TCA TCC AGG AAG GCG TCA TAC T  3’), tdTomato (Forward: 5’- AGC AAG
GGC GAG GAG GTC ATC  3’ Reverse: 5’- CCT TGG AGC CGT ACA TGA ACT GG  3’), a-sma
(Forward: 5’- TCC CTG GAG AAG AGC TAC GAA  3’ Reverse: 5’- TAT AGG TGG TTT CGT GGA
TGC C  3’), vimentin (Forward: 5’- GTA CCG GAG ACA GGT GCA GT- 3’, Reverse: 5’- TTC TCT
TCC ATC TCA CGC ATC  3’), Trp53 (Forward: 5’- CTC TCC CCC GCA AAA GAA AAA  3’,
Reverse: 5’- CGG AAC ATC TCG AAG CGT TTA  3’), CD3e (Forward: 5’- ATG CGG TGG AAC ACT
TTC TGG  3’, Reverse: 5’- GCA CGT CAA CTC TAC ACT GGT  3’), F4/80 (Forward: 5’- TGA CTC
ACC TTG TGG TCC TAA  3’, Reverse: 5’- CTT CCC AGA ATC CAG TCT TTC C  3’), or E-Cadherin
(Forward: 5’- GCT CTC ATC ATC GCC ACA G- 3’, Reverse: 5’- GAT GGG AGC GTT GTC ATT G- 3’)
using 18S (Forward: 5’- CGC TTC CTT ACC TGG TTG AT  3’, Reverse: GAG CGA CCA AAG GAA
CCA TA  3’) or 36B4 (Forward: 5’- TCC AGG CTT TGG GCA TCA  3’, Reverse: 5’- CTT TAT CAG
CTG CAC ATC ACT CAG A  3’) as controls. Primer sequences are also included in
Supplementary file 1.
Western blot
Cell lines were washed with ice-cold PBS and scraped into RIPA buffer containing cOmplete Mini
EDTA-free Protease Inhibitor Cocktail (Roche 11836170001) and PhosSTOP Phosphatase Inhibitor
Cocktail Tablets (Roche 04906845001). Lysates were then rotated at 4˚C for 20 min and centrifuged
for 5 min at max speed in a tabletop centrifuge at 4˚C. Organoids were resuspended in ice-cold PBS
containing cOmplete Mini EDTA-free Protease Inhibitor Cocktail and PhosSTOP Phosphatase Inhibi-
tor Cocktail Tablets (PBS-PPI). Organoids were then centrifuged at 3000xg for 3 min at 4˚C and
washed two times in ice-cold PBS-PPI. Cell pellets were resuspended in TNET buffer (1% Triton
X-100, 150 mM NaCl, 5 mM EDTA, and 50 mM Tris ph 7.5) containing cOmplete Mini EDTA-free
Protease Inhibitor Cocktail and PhosSTOP Phosphatase Inhibitor Cocktail Tablets, incubated on ice
for 10 min, and passed through a 26 gauge needle three times. Lysates were centrifuged for 10 min
at max speed in a tabletop centrifuge at 4˚C. Protein concentration was quantified using the Pierce
BCA Protein Assay Kit (Pierce 23225). Western blots were performed using primary antibodies
against PC (Santa Cruz sc-271493, 1:100 dilution), ME1 (Proteintech 16619–1-AP, 1:250 dilution), or
b-actin (Cell Signaling Technologies 8457, 1:10,000 dilution).
Quantification and statistical analysis
GraphPad Prism software was used for statistical analysis. All statistical information is described in
the figure legends.
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